NCT05930119

HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study

A Phase 1, Open-label, 4-period, Randomized 6-sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Hutchmed · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers

Conditions

• Intrahepatic Cholangiocarcinoma

Interventions

Type	Name	Description
DRUG	HMPL-453	300 mg HMPL-453
DRUG	Rabeprazole	20 mg of rabeprazole will be administered by mouth once daily.

Timeline

• Start date: 2023-03-17
• Primary completion: 2023-08-28
• Completion: 2023-08-28
• First posted: 2023-07-05
• Last updated: 2023-09-06

Locations

1 site across 1 country: China